Abstract
Parkinsons disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.
Keywords: Parkinson's disease, endocannabinoids, synaptic plasticity, neuroinflammation
Current Pharmaceutical Design
Title: The Endocannabinoid System in Parkinsons Disease
Volume: 14 Issue: 23
Author(s): Massimiliano Di Filippo, Barbara Picconi, Alessandro Tozzi, Veronica Ghiglieri, Aroldo Rossi and Paolo Calabresi
Affiliation:
Keywords: Parkinson's disease, endocannabinoids, synaptic plasticity, neuroinflammation
Abstract: Parkinsons disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.
Export Options
About this article
Cite this article as:
Di Filippo Massimiliano, Picconi Barbara, Tozzi Alessandro, Ghiglieri Veronica, Rossi Aroldo and Calabresi Paolo, The Endocannabinoid System in Parkinsons Disease, Current Pharmaceutical Design 2008; 14 (23) . https://dx.doi.org/10.2174/138161208785740072
DOI https://dx.doi.org/10.2174/138161208785740072 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease
Medicinal Chemistry Reviews - Online (Discontinued) Screening and Analysis of Hypolipidemic Components from Shuangdan Capsule Based on Pancreatic Lipase
Current Bioinformatics Exploring the Benefits of Cellular Models to Uncover Bioactive Polyphenols for Neurodegeneration
Current Pharmaceutical Design A Systematic Review on the Sinomenine Derivatives
Mini-Reviews in Medicinal Chemistry Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease
Current Alzheimer Research An Upcoming Approach to Alzheimer's Disease: Ethnopharmacological Potential of Plant Bioactive Molecules
Current Medicinal Chemistry Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease
Current Alzheimer Research Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
CNS & Neurological Disorders - Drug Targets Role of Polyglycine Repeats in the Regulation of Glycogen Synthase Kinase Activity
Protein & Peptide Letters